Sixth Street Welcomes Julian Salisbury as Partner and Co-Chief Investment Officer
28.7.2023 14:33:00 EEST | Business Wire | Press release
Sixth Street, a leading global investment firm, today announced that Julian Salisbury will become a partner of the firm and serve as Co-Chief Investment Officer alongside Chief Executive Officer Alan Waxman and Co-President Joshua Easterly. Salisbury is expected to start in early 2024 and will help lead Sixth Street alongside Waxman, Easterly, Vice Chairman R. Martin Chavez, Co-President David Stiepleman and the firm’s Executive Committee.
Salisbury brings to Sixth Street over 25 years of experience building and leading private and public markets investing businesses. He comes to the firm after a distinguished career at Goldman Sachs, where he most recently served as Chief Investment Officer of the Asset and Wealth Management Division. In that role, he was responsible for $2.7 trillion in assets, including more than $450 billion in alternative investments. Salisbury was previously Co-Head of Goldman Sachs Asset Management and Global Head of the Merchant Banking Division.
Prior to forming Sixth Street in 2009, many of the firm’s co-founding partners worked closely with Salisbury at Goldman Sachs while building and leading investing businesses focused on growth investing, alternative energy, real estate, direct lending, and public markets strategies, among others.
“Sixth Street’s culture is the foundation of everything we do, and Julian is a seamless fit into our firm. He has distinguished himself time and again as a superstar investor and business builder and, more importantly, as a trustworthy and reliable partner,” said Sixth Street Chief Executive Officer Alan Waxman. “Julian understands how asset owners’ needs and objectives drive the flow of capital around the world, and he embodies our firm’s values of teamwork, integrity, entrepreneurship, and making a positive impact on our communities. We first got to know each other in 2002 while working on an investment in a Swiss cable company, and since then my partners and I have cheered Julian on as he has become one of the industry’s best investors and business leaders. We are incredibly excited to be back working with him again.”
Salisbury’s career is defined by an extraordinary range of investing, business-building, and leadership experience throughout the Americas, Europe, and Asia. In addition to his role as CIO of Asset and Wealth Management, he co-chaired investment committees at Goldman Sachs across all direct private strategies including growth, real estate, private credit, private equity, and infrastructure. He was named to the Goldman Sachs Management Committee in 2017 and previously co-chaired the firm’s Partnership Committee. Salisbury serves numerous charitable and community-focused organizations, including as a director on the boards of Sponsors for Educational Opportunity (SEO) and Save the Children.
“Alan and the team at Sixth Street have assembled the exact kind of organization I would want if I were creating an investment firm from the ground up. Sixth Street’s culture, platform architecture, and investment philosophy fully align with what I consider the model for how to build and operate a modern investment firm,” said incoming Sixth Street Partner and Co-Chief Investment Officer Julian Salisbury. “While leaving Goldman Sachs was a difficult decision, this was a unique opportunity to reunite with a group of people for whom I have deep, longstanding respect. Alan and I have been colleagues and friends for more than twenty years, and I am incredibly excited to work with him, Josh, David, and Marty again as a member of the powerful investing ecosystem the Sixth Street partner group has cultivated. There really is no other firm I would have considered joining, and I am excited for all that I know we will achieve together.”
As a global investment firm designed for cross-platform collaboration at scale, Sixth Street pursues a highly flexible investment mandate: the firm invests for growth, builds new partnerships, acquires assets, provides direct financing, and regularly creates first-of-their-kind capital solutions for companies and assets customized to meet the strategic objectives of management teams. Sixth Street’s more than 500 investment and control-side professionals operate as one unified team working on behalf of the firm’s institutional investors and their beneficiaries around the world. The firm’s investments and strategic partnerships across sectors and geographies have included Airbnb, AirTrunk, Bay FC, Biohaven, FC Barcelona, Legends, Real Madrid, San Antonio Spurs, and Spotify, among many others.
About Sixth Street
Sixth Street is a leading global investment firm with over $65 billion in assets under management and committed capital. The firm’s Sixth Street TAO platform also includes Talcott Financial Group, an international life insurance group with $123 billion in assets under management. Sixth Street uses its long-term flexible capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. For more information, follow Sixth Street on social media and visit www.sixthstreet.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230728413795/en/
Contact information
Media
Sixth Street
Patrick Clifford
pclifford@sixthstreet.com
+1-646-906-4339
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
